A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples

Journal of Molecular Diagnostics

Volumn 12, Issue 6, 2010, Pages 750-756

  Setty, Prashanth ^a   Hammes, Jennifer ^a   Rothämel, Thomas ^b   Vladimirova, Valentina ^a   Kramm, Christof M ^c   Pietsch, Torsten ^a   Waha, Andreas ^a  

^a UNIVERSITY OF BONN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DNA ISOLATION; DNA TEMPLATE; EXON; FEMALE; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; INFANT; MALE; PRESCHOOL CHILD; PYROSEQUENCING; SCHOOL CHILD; SENSITIVITY ANALYSIS;

EID: 78049359978     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2010.090237     Document Type: Article

References (32)

1. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD: IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765-773
2. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215-225, 2002; discussion 226-229
3. Ohgaki H, Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007, 170:1445-1453 (Pubitemid 47339290)
4. Waha A, Felsberg J, Hartmann W, von dem Knesebeck A, Mikeska T, Joos S, Wolter M, Koch A, Yan PS, Endl E, Wiestler OD, Reifenberger G, Pietsch, T, Waha, A. Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. Cancer Res 2010, 70(4):1689-1699
5. Raffel C, Frederick L, O'Fallon JR, Atherton-Skaff P, Perry A, Jenkins RB, James CD: Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res 1999, 5:4085-4090 (Pubitemid 30013789)
6. Sung T, Miller DC, Hayes RL, Alonso M, Yee H, Newcomb EW: Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 2000, 10:249-259 (Pubitemid 30181093)
7. Cheng Y, Ng HK, Zhang SF, Ding M, Pang JC, Zheng J, Poon WS: Genetic alterations in pediatric high-grade astrocytomas. Hum Pathol 1999, 30:1284-1290 (Pubitemid 29534288)
8. Bredel M, Pollack IF, Hamilton RL, James CD: Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 1999, 5:1786-1792 (Pubitemid 29334460)
9. Pollack IF, Hamilton RL, Finkelstein SD, Campbell JW, Martinez AJ, Sherwin RN, Bozik ME, Gollin SM: The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 1997, 57:304-309
10. Rickert CH, Strater R, Kaatsch P, Wassmann H, Jurgens H, Dockhorn-Dworniczak B, Paulus W: Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. Am J Pathol 2001, 158:1525-1532 (Pubitemid 32281316)
11. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW: An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812
12. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009, 174:1149-1153
13. Xu X, Zhao J, Xu Z, Peng B, Huang Q, Arnold E, Ding J: Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem 2004, 279:33946-33957 (Pubitemid 39063045)
14. Illingworth JA, Tipton KF: Purification and properties of the nicotinamide-adenine dinucleotide phosphate-dependent isocitrate dehydrogenase from pig liver cytoplasm. Biochem J 1970, 118:253-258
15. Geisbrecht BV, Gould SJ: The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J Biol Chem 1999, 274:30527-30533
16. Thompson CB: Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med 2009, 360:813-815
17. Jennings GT, Minard KI, McAlister-Henn L: Expression and mutagenesis of mammalian cytosolic NADP+-specific isocitrate dehydrogenase. Biochemistry 1997, 36:13743-13747
18. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109
19. Pietsch T, Taylor MD, Rutka JT: Molecular pathogenesis of childhood brain tumors. J Neurooncol 2004, 70:203-215
20. Ducray F, El Hallani S, Idbaih A: Diagnostic and prognostic markers in gliomas. Curr Opin Oncol 2009, 21:537-542
21. Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, Suzuki H, Tominaga T: Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 2009, 100:1996-1998
22. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008, 116:597-602
23. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT, Collins VP: IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009, 11:341-347
24. Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN: Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 2009, 68:1319-1325
25. Mane SM, Meltzer SJ, Gutheil JC, Kapil V, Lee EJ, Needleman SW: RAS gene activation in acute myelogenous leukemia: analysis by in vitro amplification and DNA base sequence determination. Genes Chromosomes Cancer 1990, 2:71-77
26. Cogswell PC, Morgan R, Dunn M, Neubauer A, Nelson P, Poland-Johnston NK, Sandberg AA, Liu E: Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. Blood 1989, 74:2629-2633
27. Ball ED, Mills LE, Neubauer A, Liu E: Detection of minimal acute myeloid leukemia cells in bone marrow by probing for mutated ras oncogenes using the polymerase chain reaction. Prog Clin Biol Res 1990, 333:499-506
28. Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD: A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 2009, 390:547-551
29. Ronaghi M, Uhlen M, Nyren P: A sequencing method based on real-time pyrophosphate. Science 1998, 281;363-365
30. Fakhrai-Rad H, Pourmand N, Ronaghi M: Pyrosequencing: an accurate detection platform for single nucleotide polymorphisms. Hum Mutat 2002, 19:479-485
31. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A, Bardelli A: IDH1 mutations at residue p.R132 IDH1(R132) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009, 30:7-11
32. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009, 27:4150-4154